MedPath

Chlorhexidine Skin Application for Prevention of Infection in Infants Weighing less than 1500 g at Birth (CAPS)

Phase 3
Conditions
Health Condition 1: null- Neonatal sepsis
Registration Number
CTRI/2014/05/004599
Lead Sponsor
ICMR
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
1282
Inclusion Criteria

Intramural infants with birth weight less than 1500 g

Exclusion Criteria

Birth weight less than750 g; Major congenital malformations; Total duration of positive pressure ventilation (PPV) > 3 mins OR chest compressions; Shock- requiring inotropes >10 mic/kg/min

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Sepsis within first 7 days of lifeTimepoint: Within first 7 days of life
Secondary Outcome Measures
NameTimeMethod
Body temperature at 0, 5, 15, 30 minutes after applicationTimepoint: 30 minutes;Chlorhexidine percutaneous absorptionTimepoint: 48 ±6 hours;Readmissions and mortality rates within neonatal periodTimepoint: 28 days;Skin colonization ratesTimepoint: 24 ±6 hours;Skin condition (as measured by NSCS)Timepoint: 24 ±6 hours
© Copyright 2025. All Rights Reserved by MedPath